Rein Therapeutics, Inc. (RNTX) stock
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)
Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%
Rein Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rein Therapeutics's ebitda for the twelve months ending Dec 31, 2025 was -$50.63M. For fiscal 2025 it was -$50.63M. The highest annual figure on record is -$12.57M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.63M | – |
| FY2024 | Dec 31, 2024 | -$65.05M | – |
| FY2023 | Dec 31, 2023 | -$16.16M | – |
| FY2022 | Dec 31, 2022 | -$27.48M | – |
| FY2021 | Dec 31, 2021 | -$26.48M | – |
| FY2020 | Dec 31, 2020 | -$20.33M | – |
| FY2019 | Dec 31, 2019 | -$29.80M | – |
| FY2018 | Dec 31, 2018 | -$31.68M | – |
| FY2017 | Dec 31, 2017 | -$22.88M | – |
| FY2016 | Dec 31, 2016 | -$17.94M | – |
| FY2015 | Dec 31, 2015 | -$12.57M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$32.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.87M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$42.80M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.15M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.98M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.66M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.75M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.99M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.18M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.33M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.81M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.27M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.28M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.93M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.41M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.72M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.00M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.39M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.93M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.57M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.41M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.17M | – |
See a number that looks wrong?